Updated BARDA Coronavirus Funding Opportunities

June 2020

Biomedical Advanced Research and Development Authority (BARDA) has two open funding opportunities focused on coronavirus, Broad Agency Announcement (BAA) and EZ-BAA. Submissions and meeting requests of coronavirus-related medical countermeasures for both opportunities is through the CoronaWatch portal. Submissions should be brief, 500-word description of the technology together with a slide deck, and/or manuscript and/or publication and/or other non-confidential information.

Please Note! Interested parties who currently have a white paper or proposal under review for any ASPR funding opportunity are not eligible for a CoronaWatch meeting related to that submission.


White paper and Quad Chart should be submitted by email. Submissions must demonstrate how the proposed technology acts as a countermeasure for SARS-CoV-2 (or COVID-19). BARDA is accepting rolling reviews, meaning completed sections can be submitted once ready.

Areas of Interest:
  • Diagnostic Assays: existing FDA-approved platforms, serology tests, as a part of FDA-approved platforms for influenza and other respiratory diseases)
  • Point-of-Care Diagnostic Assays
  • Vaccines: suitable for commercial scale production; manufacturing within the US; preference for later-stage technologies and those with data from SARS or MERS
  • Therapeutics: Proven direct-acting antivirals (in-vitro efficacy vs. human coronaviruses required), host-directed therapeutics (specifically, those indirectly inhibit the coronavirus virus lifecycle) – Please note – preference for repurposed technologies with existing FDA approval or late-stage development, as well as technologies that have reached TRL6 level. Manufacturing in the US required.
  • Respiratory protective devices
  • Advanced manufacturing technologies

White Paper and Full Proposal Submission Deadline (unless otherwise indicated): October 31, 2020

Any white papers or full proposals submissions unrelated to COVID-19 will be put into a queue.

2. Streamlined BARDA EZ-BAA Released for Novel Coronavirus Rapid Diagnostic and Vaccines

This funding opportunity aims to promote and accelerate innovation and availability of medical countermeasures.

Areas of Interest:
  • Diagnostics
  • Remote patient monitoring and diagnostic tools
  • Vaccines
  • Alternative vaccine delivery platforms (accelerated timeline), such as oral or skin- preference for technologies that have already demonstrated feasibility and/or immunogenicity in humans or animals against Influenza, SARS-CoV1 and 2, or MERS-CoV

Submission Deadline: June 30th, 2020

Abstracts up to $750,000

An IND submission is required upon completion of BARDA DRIVe funding.